Literature DB >> 16823384

Linking the PANSS, BPRS, and CGI: clinical implications.

Stefan Leucht1, John M Kane, Eva Etschel, Werner Kissling, Johannes Hamann, Rolf R Engel.   

Abstract

To understand what given scores of the Brief Psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) mean from a clinical point of view is important for the translation of research results into practice. We therefore (a) compared the absolute change of the BPRS/PANSS with the Clinical Global Impressions Ratings (CGI) -improvement score and the change of the CGI severity score, (b) analyzed whether the severity of illness at baseline had an impact on the latter association, and (c) attempted to replicate previous BPRS findings using a completely different data set based upon the PANSS-derived BPRS. The method used was equipercentile linking of BPRS and CGI ratings from 14 drug trials in acutely ill patients with schizophrenia (n=5970). An absolute reduction of the BPRS/PANSS by approximately 10/15 points corresponded to a CGI change of 'minimally improved' and to a change of the CGI severity score by one severity step. However, the latter associations depended on the severity of symptoms at baseline. Less severely ill patients required less BPRS/PANSS total score reduction to achieve the same CGI-improvement score than more severely ill patients. This effect of initial severity was attenuated using percentage rather than absolute BPRS/PANSS reduction scores. The linking analysis between the absolute BPRS/PANSS reduction and the CGI may have an implication for the interpretation of efficacy differences found in clinical trials, and for sample size estimations. Clinicians seem to base CGI ratings on relative change rather than on absolute change of symptoms.

Entities:  

Mesh:

Year:  2006        PMID: 16823384     DOI: 10.1038/sj.npp.1301147

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  74 in total

1.  Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods.

Authors:  Nikie Korver; Piotr J Quee; Heleen B M Boos; Claudia J P Simons; Lieuwe de Haan
Journal:  Int J Methods Psychiatr Res       Date:  2012-03-15       Impact factor: 4.035

2.  On the concept of remission in schizophrenia.

Authors:  Stefan Leucht; Romain Beitinger; Werner Kissling
Journal:  Psychopharmacology (Berl)       Date:  2007-07-06       Impact factor: 4.530

Review 3.  Methodological issues in current antipsychotic drug trials.

Authors:  Stefan Leucht; Stephan Heres; Johannes Hamann; John M Kane
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

Review 4.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

5.  Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods.

Authors:  Rebecca Schennach; Hans-Jürgen Möller; Michael Obermeier; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Ilja Spellmann; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2015-07-14       Impact factor: 4.035

6.  Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.

Authors:  Todd S Woodward; Kwanghee Jung; Geoffrey N Smith; Heungsun Hwang; Alasdair M Barr; Ric M Procyshyn; Sean W Flynn; Mark van der Gaag; William G Honer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-15       Impact factor: 5.270

7.  [Response and remission in schizophrenic subjects].

Authors:  J Zimmermann; A Wolter; N R Krischke; U W Preuss; T Wobrock; P Falkai
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

8.  The Harms of Antipsychotic Drugs: Evidence from Key Studies.

Authors:  Thomas J Moore; Curt D Furberg
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

9.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2017-10-10       Impact factor: 13.382

Review 10.  Benzodiazepines for schizophrenia.

Authors:  Markus Dold; Chunbo Li; Magdolna Tardy; Vesal Khorsand; Donna Gillies; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.